Literature DB >> 33417654

Multimorbidity patterns among COVID-19 deaths: proposal for the construction of etiological models.

Julián A Fernández-Niño1, John A Guerra-Gómez2, Alvaro J Idrovo3.   

Abstract

OBJECTIVES: To describe patterns of multimorbidity among fatal cases of COVID-19, and to propose a classification of patients based on age and multimorbidity patterns to begin the construction of etiological models.
METHODS: Data of Colombian confirmed deaths of COVID-19 until June 11, 2020, were included in this analysis (n=1488 deaths). Relationships between COVID-19, combinations of health conditions and age were explored using locally weighted polynomial regressions.
RESULTS: The most frequent health conditions were high blood pressure, respiratory disease, diabetes, cardiovascular disease, and kidney disease. Dyads more frequents were high blood pressure with diabetes, cardiovascular disease or respiratory disease. Some multimorbidity patterns increase probability of death among older individuals, whereas other patterns are not age-related, or decrease the probability of death among older people. Not all multimorbidity increases with age, as is commonly thought. Obesity, alone or with other diseases, was associated with a higher risk of severity among young people, while the risk of the high blood pressure/diabetes dyad tends to have an inverted U distribution in relation with age.
CONCLUSIONS: Classification of individuals according to multimorbidity in the medical management of COVID-19 patients is important to determine the possible etiological models and to define patient triage for hospitalization. Moreover, identification of non-infected individuals with high-risk ages and multimorbidity patterns serves to define possible interventions of selective confinement or special management.

Entities:  

Keywords:  Betacoronavirus; Colombia; medical care; mortality; multimorbidity

Year:  2020        PMID: 33417654      PMCID: PMC7778468          DOI: 10.26633/RPSP.2020.166

Source DB:  PubMed          Journal:  Rev Panam Salud Publica        ISSN: 1020-4989


Currently, the practice of medicine is complex, and it is even more so when faced with a new infection such as COVID-19.[1] Scientific knowledge provides guidelines for having an effective medicine, but when people have chronic diseases, more than one disease (co-occurrence), and receive several medicines, clinical practice becomes an even bigger challenge, especially when these chronic diseases do not receive adequate care.[2] In addition, conditions such as physical disability, mostly also as a consequence of these chronic diseases, could also increase vulnerability to complications from other different diseases. Evidence shows that multimorbidity is one of the clinical characteristics that most complicates the care of infected people,[3] which is clearly true for COVID-19 as well. Valderas et al.[4] defined multimorbidity as the “presence of multiple diseases in one individual”, where comorbidity is just one of the possible forms of multimorbidity. For these authors comorbidity is the “presence of additional diseases in relation to an index disease in one individual”; therefore, the co-occurrence of various pre-existing diseases with COVID-19 infection is not necessarily comorbidity. Multimorbidity among individuals with COVID-19 was described early among the first reported patients in the specialized literature,[5] and it is a frequent finding in published studies.[6,7] However, the term comorbidity continues to be used incorrectly in most published studies. A critical reading of previous studies allows us to identify that, for the most of these. The objective of this study was to explore the effect of single diseases on the clinical severity or the risk of fatality among patients with diagnosis of COVID-19. This leaves out more complex approaches such as those that configure vulnerability of older adults as a construct beyond the effect of single diseases or their simple sum. Therefore, it is necessary to study multimorbidity as a multidimensional condition, which incorporates the joint presence and the interactions of all the health conditions. A deeper analysis should emphasize the type of potential relationships between health conditions, whether they are under medical control or not, as well as other sources of vulnerability such as disability, functional dependence on other people, the presence of geriatric syndromes or even the social and economic vulnerabilities, among others. Understanding the multimorbidity associated with emerging diseases such as COVID-19 is important to classify patients, identify possible etiological models, and define differential medical management guidelines.[8] In critical situations such as the COVID-19 pandemic, a good classification of infected people is important to improve their care. For those who can seek hospital care, this can be done in the initial triage, and for those who are cared for at home, it will serve to identify the risk of infection severity. In addition, recognizing the multimorbidity as a multidimensional and complex condition will allow the development of more complex risk classifications, to identify subjects who need greater vigilance at the community and hospital level, or to formulate “telework” recommendations in certain occupations. The wide variety of multimorbidity patterns includes the most frequent co-occurrences that were evident since the beginning of the pandemic, and the co-occurrences with less frequency that appear every time there are more cases, and perhaps it will include orphan diseases,[9,10] and those of endemic foci.[11] In these circumstances, low prevalence signifies more clinical complexity. In this study, we used Colombian data to describe patterns or multimorbidity among individuals diagnosed with COVID-19.

MATERIAL AND METHODS

Official nominal data of confirmed cases of COVID-19 for Colombia, with a cutoff date of June 11, 2020 throughout the country were included in this study. This data had a good performance according to an analysis based on Bedford’s law.[12] Data used in this study correspond to the official report that is constructed daily with the cases that have been confirmed by the National Institute of Health, based on laboratory tests (reflex nasal swab reverse transcription PCR). Although it has a lag of a few days, it is the most reliable source of data on the SARS-CoV-2 pandemic in Colombia. The other available sources have greater lags and may incorporate suspected cases that did not have confirmatory laboratory tests. By that date, 17 790 cases and 1 488 deaths by COVID-19 were reported. This database has information on each case, specifically: municipality and department of occurrence, date of onset of symptoms, date of diagnosis, date of report, sex, and age. For each dead individual, the presence or absence of a predetermined list of comorbidities is reported in the database: high blood pressure (HBP), diabetes mellitus, respiratory disease, cardiovascular disease, chronic kidney disease (CKD), cerebrovascular disease, smoking, cancer, thyroid disease, autoimmune disease, and HIV. This list includes nine of the top 10 chronic diseases identified in a systematic review of measurements of multimorbidity.[13] Although smoking is not a chronic disease, it is a chronic health condition that has direct functional effects, beyond being a risk factor for other diseases, reason why it is incorporated as part of a broad definition of multimorbidity in this analysis. Individuals reported as hospitalized or in the Intensive Care Unit (ICU) were not included because they were in an intermediate stage of their medical treatment and the definitive outcome was unknown (recovery or death). Information about chronic disease among mild and moderate cases of COVID-19 is not available by the time of this analysis. The database can be requested from the Colombian Ministry of Health and Health Protection. Statistical methods. First, the description of the prevalence of each disease among fatal cases was made individually, without considering the co-occurrence of other health conditions. These patterns were compared between age groups using x2 test. Subsequently, all possible disease dyads and triads were identified, characterizing multimorbidity. With this procedure the 10 most prevalent (>2%) multimorbidity patterns were recognized. For the estimation of prevalences, it was assumed that the individuals observed were a random sample of cases from the total population of COVID-19 cases that will be observed in Colombia at the end of the pandemic, which is reasonable given that the country has several weeks with sustained local transmission. Given this assumption, and that the prevalences are exceptionally low, exact 95% Clopper-Pearson confidence intervals were estimated.[14] Cluster at the department level were considered to consider the spatial correlation of observations. Under 60 years 60 years and more Only one condition co-occurrence Prevalence (%) 95% CI Prevalence (%) 95% CI HBP 26.80 20.84 33.45 39.76 33.07 46.74 Respiratory disease 7.20 4.56 10.70 19.46 14.82 24.82 Diabetes 18.36 14.72 22.48 18.81 15.55 22.44 Cardiovascular disease 7.94 5.98 10.30 16.77 13.75 20.17 Kidney disease 5.71 4.58 7.57 11.86 10.20 13.69 Obesity 18.61 14.14 23.78 5.19 4.13 6.43 Smoking 3.97 1.87 7.31 5.19 3.61 7.20 Stroke 0.74 0.09 2.65 4.63 3.62 5.93 Thyroid disease 1.99 0.76 4.19 4.54 2.33 7.89 Cancer 2.48 1.07 4.87 3.89 2.38 5.97 Autoimmune disease 3.97 1.38 8.73 1.11 0.39 2.38 HIV 2.48 0.70 6.75 0.36 0.10 0.91 Two or more conditions co-occurrence HBP + Diabetes 9.68 7.09 12.82 11.03 8.66 13.78 HBP + Cardiovascular disease 3.23 1.69 5.53 8.71 6.19 11.87 HBP + Respiratory disease 2.25 1.20 3.77 7.60 5.67 9.94 HBP + Chronic Kidney Disease 1.99 1.16 3.17 5.75 4.42 7.32 Cardiovascular disease + Respiratory disease 1.24 0.45 2.71 3.99 2.69 5.67 Diabetes + Cardiovascular disease 2.48 1.31 4.23 3.71 2.71 4.93 HBP + Obesity 5.21 3.18 7.99 2.87 2.16 3.74 Diabetes + Cardiovascular disease + HBP 1.49 0.54 3.25 2.50 1.76 3.45 Smoking + Respiratory disease 0.74 0.16 2.15 2.22 1.48 3.21 Diabetes + Obesity 4.96 3.46 6.86 1.67 0.88 2.87 Only dyads and triads with higher prevalences. HBP, high blood pressure. A locally weighted polynomial regression was fitted between each morbidity and age (continuous) to identify patterns of association. This regression was chosen because it uses a nonparametric method, where the assumptions of conventional regressions can be relaxed.[15] This bivariate exploration included as dependent variable the presence or not of multimorbidity, for each type of pattern, age as the exposure variable, and sex as confounder. Finally, we proposed three simple qualitative models of multimorbidity for COVID-19 using configurations described by Valderas et al.[4] The analyses were performed with the statistical software Stata 16 (Stata Corporation, USA). Ethical considerations. This study was carried out during a sanitary crisis. Data was collected by territorial health secretaries and organized by the Colombian National Institute of Health, and it was freely available to the public in its webpage. There was no access to personal data or variables that allowed the identification or localization of the participants. This study was considered as an response to the World Health Organization’s call of “… to learn as much as possible as quickly as possible, in order to inform the ongoing public health response, and to allow for proper scientific evaluation of new interventions being tested”.[16] Obtained results were informed to the Colombian Ministry of Health to support health policies during the pandemic.

RESULTS

In this study, 1 488 deaths were analyzed and 61% of them occurred in men. The mean of age of the fatal outcomes was 67.59 years (median: 69 years; percentiles: p10= 46, p25= 58, p75= 79, p90= 86 years) and only 27.19% of the deaths occurred among people under 60 years. Table 1 shows the main health conditions accompanying COVID-19 infection, with their respective prevalences and 95% confidence intervals, according to the age groups (under 60, and 60 years and more). Prevalences of respiratory, cardiovascular or kidney diseases, stroke, HBP + cardiovascular disease, HBP + respiratory disease, HBP + chronic kidney disease were higher among individuals with 60 or more years. Obesity was more frequent among under 60 years old. Figure 1 shows that multimorbidity prevalence increases markedly among those over 80 years.
TABLE 1.

Prevalence of health conditions[¥] among fatal cases of COVID-19 in Colombia

 

Under 60 years

60 years and more

Only one condition co-occurrence

Prevalence (%)

95% CI

Prevalence (%)

95% CI

HBP

26.80

20.84

33.45

39.76

33.07

46.74

Respiratory disease

7.20

4.56

10.70

19.46

14.82

24.82

Diabetes

18.36

14.72

22.48

18.81

15.55

22.44

Cardiovascular disease

7.94

5.98

10.30

16.77

13.75

20.17

Kidney disease

5.71

4.58

7.57

11.86

10.20

13.69

Obesity

18.61

14.14

23.78

5.19

4.13

6.43

Smoking

3.97

1.87

7.31

5.19

3.61

7.20

Stroke

0.74

0.09

2.65

4.63

3.62

5.93

Thyroid disease

1.99

0.76

4.19

4.54

2.33

7.89

Cancer

2.48

1.07

4.87

3.89

2.38

5.97

Autoimmune disease

3.97

1.38

8.73

1.11

0.39

2.38

HIV

2.48

0.70

6.75

0.36

0.10

0.91

Two or more conditions co-occurrence

 

 

 

 

 

 

HBP + Diabetes

9.68

7.09

12.82

11.03

8.66

13.78

HBP + Cardiovascular disease

3.23

1.69

5.53

8.71

6.19

11.87

HBP + Respiratory disease

2.25

1.20

3.77

7.60

5.67

9.94

HBP + Chronic Kidney Disease

1.99

1.16

3.17

5.75

4.42

7.32

Cardiovascular disease + Respiratory disease

1.24

0.45

2.71

3.99

2.69

5.67

Diabetes + Cardiovascular disease

2.48

1.31

4.23

3.71

2.71

4.93

HBP + Obesity

5.21

3.18

7.99

2.87

2.16

3.74

Diabetes + Cardiovascular disease + HBP

1.49

0.54

3.25

2.50

1.76

3.45

Smoking + Respiratory disease

0.74

0.16

2.15

2.22

1.48

3.21

Diabetes + Obesity

4.96

3.46

6.86

1.67

0.88

2.87

Only dyads and triads with higher prevalences.

HBP, high blood pressure.

FIGURE 1.

Prevalence of the 10 main dyads and triads identified among fatal cases of COVID-19 in Colombia, by age group

Figure 2 shows the probability of each morbidity according to age, considered separately. In general, there is a tendency to increase the probability of each morbidity with increasing age, and only high blood pressure, cardiovascular disease, and kidney chronic disease tend to be linear. In contrast, obesity decreases the probability of occurrence with increasing age, whereas smoking, thyroid disease, cancer, autoimmune disease, and HIV have not a clear trend towards increase or decrease. In short, among the fatal cases of COVID-19, the occurrence of multimorbidities is positively associated with age, as is known. One of the exceptions is obesity, which is more frequent in fatal young cases. This is also shown by the fact that obesity has a higher occurrence in fatal cases in young people.
FIGURE 2.

Locally weighted polynomial regressions between COVID-19, health condition and age, among fatal cases in Colombia[*]

Figure 3 shows the probability of each pattern of multimorbidity according to the 12 top complex health conditions (COVID-19 + two or more health conditions) according to age. In these cases, the relationships are heterogeneous and non-linearity is common. The COVID-19 + high blood pressure + diabetes pattern has an inverted U distribution and it is very important due to its relative high prevalence. It contrasts with the linear relationship of COVID-19 + high blood pressure + respiratory disease. In summary, not all multimorbidity increases with age, as is commonly thought.
FIGURE 3.

Locally weighted polynomial regressions between COVID-19, complex patterns of health conditions and age, among fatal cases in Colombia[*]

DISCUSSION

Findings of this study indicate that multimorbidity is an important phenomenon to consider in the context of the COVID-19 pandemic. The co-occurrences of COVID-19 with different combinations of diseases including high blood pressure, diabetes mellitus, obesity, cardiovascular, respiratory, and CKD have a high frequency among individuals deceased by COVID-19 in Colombia and other countries. Identification of these multimorbidity patterns among individuals diagnosed with SARS-CoV-2 infection could provide insights for patient triage for hospitalization, and basic care at home according to the estimated risk. Moreover, identification of non-infected individuals with high-risk ages and specific multimorbidity patterns could serve to define possible interventions of selective confinement or special management. Only includes health conditions separately. Includes patterns of two or more health conditions. The top six morbidities identified have a strong relationship with age (HBP, respiratory disease, diabetes, cardiovascular disease, CKD, and obesity). Most of these six associations were positive but not linear, except obesity and diabetes where the association decreases with age after a turning point. Given that these results are conditional on death, these relationships could mainly be explained by survivor bias, since diabetes and obesity are not only more prevalent in young adults, but also, in turn, this is the effect of higher mortality before 60 years of age. However, the importance of this finding is that it precisely identifies that diseases such as obesity and diabetes are more relevant in adults younger than 60 years as potential factors associated with COVID-19 fatality. Other diseases such as thyroid disease, HIV, autoimmune disease, stroke, and cancer seem to be important, although not age-related. These diseases seem to be important regardless of age as factors associated with fatal outcomes of COVID-19 infection. With the multimorbidity classification by Valderas et al[4] it is possible to identify that among individuals diagnosed with COVID-19 there are different types of multimorbidity. We propose that there are least three possible models between COVID-19 and chronic diseases (figure 4). In the first model, chronic disease is an effect modifier of SARS-CoV-2 infection, increasing the risk of complications and severity. The second model incorporates the existence of common causes associated with the chronic disease and related clinical or social factors. Finally, in model 3 there is only a temporary concurrence of the chronic disease and COVID-19 infection, but there is neither relationship among them, nor they have common causes. To determine which configurations are more frequent and which ones apply to each chronic disease, cohort studies that consider the nature of these relationships are required.
FIGURE 4.

Proposed models between chronic disease and COVID-19 infection observed among Colombian patients[*]

In response to this situation with different etiological models, it is possible to improve the proposed guidelines for managing chronic diseases when they co-occur with COVID-19. For instance, guidelines for COVID-19 individuals with high blood pressure,[17] diabetes,[18,19] cardiovascular disease,[20] kidney disease,[21] metabolic and bariatric surgery,[22] endocrine surgery,[23] lung cancer,[24] stroke,[25] and systemic sclerosis.[26] There are also recommendations for older adults with multimorbidity and polypharmacy.[27,28] These types of practices and discussions associated with the proposed changes to manage patients are evidence of the complexity of COVID and the associated multimorbidity. However, the more difficult cases will be individuals with COVID-19 and complex diseases with low prevalence. Simple theoretical models; in the clinical practice there are many variables involved. Multimorbidity should be understood as a vulnerability condition itself, and more than the additive sum of chronic diseases. Multimorbidity is like a concentration of expressions in a unique health-disease process, which means that it’s the joint result of the risk factors and pathophysiological changes associated with each of the health conditions involved. Among older adults, this medical complexity configures the frailty syndrome,[29] that affects physiological reserves and multiple systems, making older adults more susceptible to complications and death from COVID-19, like from other diseases. This could explain the well-recognized relationship between age and severity in COVID-19, which is undoubtedly measured by multimorbidity. For this reason, in this study multimorbidity was included as an underlying latent variable in our analysis. Similar experiences were found with the Patient-Centered Clinical Method (PCCM) questionnaire in Canada, where the complexity of multimorbidity and associated factors can be comparable.[30] There are even other analyses comparing ways of approaching multimorbidity, which suggests that hierarchical cluster analysis shows comorbidity, while exploratory factor analysis multimorbidity.[31] Subsequent analyses can use this approach to build scales of risk of death and complications. In addition, diseases that co-occur in time and place configure the existence of a syndemic. For Singer and Clair, a syndemic occurs because there are social characteristics that are acting as determinants, so adequate management requires a more comprehensive approach.[32] In this case, COVID-19 co-occurs with different multimorbidity patterns, which is specific to a complex emergent disease. Results presented here should be interpreted taking into account some methodological limitations. First, in this study other conditions that have been used in multimorbidity indices were not available: (osteo)arthritis, hearth failure, depression, osteoporosis, peripheral arterial occlusive disease, vision problems, dementia, hearing problems and angina pectoris[13]. Colombian official database only includes the 10 conditions reported in this study. However, with the exception of heart failure and angina, all other conditions have higher prevalences among older adults. For this reason, they would not be directly associated with the risk of becoming infected or dying from COVID-19. Heart failure and angina would be covered by the label “cardiovascular disease”, so we consider that the most relevant morbidities associated with COVID-19 severity were considered. Another limitation is related to the non-inclusion of socioeconomic health conditions, disability and functional dependence, geriatric syndromes, and mental health problems (mainly depression and dementia). Although their relationship with the probability of death is more direct, if they are theoretically part of multimorbidity from a broader perspective[8], and could indirectly affect the clinical outcome of the disease, by affecting access to health services, adherence to treatment or its effectiveness, as well as the biological interaction of the underlying conditions. Although the analyses presented here are limited to the patterns of multimorbidity with the highest occurrence, it is important to note that this situation can occur with diseases of lesser occurrence (including neglected diseases) which could be important in some regions. In this case, the medical care becomes a big challenge for clinicians. In conclusion, in this study the patterns of multimorbidity among people diagnosed with COVID-19 in Colombia during the acute period of infection were presented. Undoubtedly, in the future, more multimorbidity patterns will be known. Similar analyses in different regions that incorporate the different epidemiological patterns[33] may facilitate the care of people with COVID-19, and the prevention of transmission among high-risk populations.

Funding.

None declared.

Disclaimer.

Authors hold sole responsibility for the views expressed in the manuscript, which may not necessarily reflect the opinion or policy of the RPSP/PAJPH and/or PAHO.
  29 in total

1.  Syndemics and public health: reconceptualizing disease in bio-social context.

Authors:  Merrill Singer; Scott Clair
Journal:  Med Anthropol Q       Date:  2003-12

Review 2.  The measurement of multiple chronic diseases--a systematic review on existing multimorbidity indices.

Authors:  Claudia Diederichs; Klaus Berger; Dorothee B Bartels
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-11-26       Impact factor: 6.053

3.  Multimorbidity: redesigning health care for people who use it.

Authors:  Chris Salisbury
Journal:  Lancet       Date:  2012-05-10       Impact factor: 79.321

4.  COVID-19 Pandemic: Considerations for Safe Medication Use in Older Adults with Multimorbidity and Polypharmacy.

Authors:  Nagham J Ailabouni; Sarah N Hilmer; Lisa Kalisch; Rhiannon Braund; Emily Reeve
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2021-05-22       Impact factor: 6.053

5.  Management of Lung Cancer During the COVID-19 Pandemic.

Authors:  Aditi P Singh; Abigail T Berman; Melina E Marmarelis; Andrew R Haas; Steven J Feigenberg; Jennifer Braun; Christine A Ciunci; Joshua M Bauml; Roger B Cohen; John C Kucharczuk; Lawrence N Shulman; Corey J Langer; Charu Aggarwal
Journal:  JCO Oncol Pract       Date:  2020-05-26

6.  Subjunctive medicine: Enacting efficacy in general practice.

Authors:  Doug Hardman; Adam W A Geraghty; Mark Lown; Felicity L Bishop
Journal:  Soc Sci Med       Date:  2019-11-21       Impact factor: 4.634

7.  A genetic model for multimorbidity in young adults.

Authors:  Sarah L Malecki; Spencer Van Mil; Justin Graffi; Elemi Breetvelt; Maria Corral; Erik Boot; Eva W C Chow; Marcos Sanches; Amol A Verma; Anne S Bassett
Journal:  Genet Med       Date:  2019-07-31       Impact factor: 8.822

8.  Primary care and multimorbidity in six Latin American and Caribbean countries.

Authors:  James Macinko; Flavia C D Andrade; Bruno P Nunes; Frederico C Guanais
Journal:  Rev Panam Salud Publica       Date:  2019-01-25

Review 9.  Assessment and treatment of older individuals with COVID 19 multi-system disease: Clinical and ethical implications.

Authors:  Fulvio Lauretani; Giulia Ravazzoni; Maria Federica Roberti; Yari Longobucco; Elisa Adorni; Margherita Grossi; Aurelio De Iorio; Umberto La Porta; Chiara Fazio; Elena Gallini; Raffaele Federici; Marco Salvi; Erika Ciarrocchi; Francesca Rossi; Marina Bergamin; Giacomo Bussolati; Ilaria Grieco; Federica Broccoli; Irene Zucchini; Giuseppe Ielo; Simonetta Morganti; Andrea Artoni; Arianna Arisi; Sara Tagliaferri; Marcello Maggio
Journal:  Acta Biomed       Date:  2020-05-11

Review 10.  Managing COVID-19 in Renal Transplant Recipients: A Review of Recent Literature and Case Supporting Corticosteroid-sparing Immunosuppression.

Authors:  Kristen M Johnson; Julie J Belfer; Gina R Peterson; Mark R Boelkins; Lisa E Dumkow
Journal:  Pharmacotherapy       Date:  2020-05-26       Impact factor: 6.251

View more
  7 in total

Review 1.  Multimorbidity matters in low and middle-income countries.

Authors:  Ana Basto-Abreu; Tonatiuh Barrientos-Gutierrez; Alisha N Wade; Daniela Oliveira de Melo; Ana S Semeão de Souza; Bruno P Nunes; Arokiasamy Perianayagam; Maoyi Tian; Lijing L Yan; Arpita Ghosh; J Jaime Miranda
Journal:  J Multimorb Comorb       Date:  2022-06-16

2.  Identifying multimorbidity profiles associated with COVID-19 severity in chronic patients using network analysis in the PRECOVID Study.

Authors:  Jonás Carmona-Pírez; Antonio Gimeno-Miguel; Kevin Bliek-Bueno; Beatriz Poblador-Plou; Jesús Díez-Manglano; Ignatios Ioakeim-Skoufa; Francisca González-Rubio; Antonio Poncel-Falcó; Alexandra Prados-Torres; Luis A Gimeno-Feliu
Journal:  Sci Rep       Date:  2022-02-18       Impact factor: 4.379

3.  Metabolomics of Multimorbidity: Could It Be the Quo Vadis?

Authors:  Pujarini Dash; Soumya R Mohapatra; Sanghamitra Pati
Journal:  Front Mol Biosci       Date:  2022-03-11

4.  Exploring the associations between polypharmacy and COVID-19-related hospitalisations and deaths: a population-based cohort study among older adults in Quebec, Canada.

Authors:  Caroline Sirois; Véronique Boiteau; Yohann Chiu; Rodica Gilca; Marc Simard
Journal:  BMJ Open       Date:  2022-03-07       Impact factor: 2.692

5.  Multimorbidity Profile of COVID-19 Deaths in Portugal during 2020.

Authors:  Paulo Jorge Nogueira; Miguel de Araújo Nobre; Cecília Elias; Rodrigo Feteira-Santos; António C-V Martinho; Catarina Camarinha; Leonor Bacelar-Nicolau; Andreia Silva Costa; Cristina Furtado; Liliane Morais; Juan Rachadell; Mário Pereira Pinto; Fausto Pinto; Antó Vaz Carneiro
Journal:  J Clin Med       Date:  2022-03-29       Impact factor: 4.241

6.  Identifying pre-existing conditions and multimorbidity patterns associated with in-hospital mortality in patients with COVID-19.

Authors:  Magda Bucholc; Declan Bradley; Damien Bennett; Lynsey Patterson; Rachel Spiers; David Gibson; Hugo Van Woerden; Anthony J Bjourson
Journal:  Sci Rep       Date:  2022-10-15       Impact factor: 4.996

Review 7.  Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease.

Authors:  Seodhna M Lynch; Guangran Guo; David S Gibson; Anthony J Bjourson; Taranjit Singh Rai
Journal:  Cells       Date:  2021-11-30       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.